Five healthy gay men contract a rare pneumonia associated with severe immunosuppression; later identified as AIDS
Learning from COVID-19
The HIV response must build on 40 years of robust science and also incorporate important lessons from the COVID-19 pandemic. The challenge is ensuring that the results of scientific research inform policies implemented at scale and enhance the delivery of programmes and healthcare practices. This can be achieved in three main ways: promote science, support action and empower people.
Centers for Disease Control and Prevention. Pneumocystis pneumonia—Los Angeles. Morbidity and Mortality Weekly Report. 30, 250–252 (1981)
Barré-Sinoussi F, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220, 868–871 (1983)
Clumeck N, et al. Acquired immune deficiency syndrome in Black Africans. Lancet 1, 642 (1983)
Alexander TS. Clinical and Vaccine Immunology. 23, 249–253 (2016)
Broder S. The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. Antiviral Research. 85, 1–18 (2010)1
Connor EM, et al. New England Journal of Medicine. 331, 1173–1180 (1994)
Baker R. FDA approves 3TC and saquinavir. Food and Drug Administration. BETA. 5, 9. PMID: 11363011 (1995 Dec)
Mann JM. Health and human rights: if not now, when? Health and Human Rights. 2(3):113–120 (1997)
Allers k, et al. Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation. Blood. 117 (10): 2791–2799 (2011)
Vernazza Pietro, Hirschel Bernard, Bernasconi Enos, Flepp Markus. HIV transmission under highly active antiretroviral therapy. Lancet. 372 (9652): 1806–1807 (November 2008)
Cohen MS, et al. Prevention of HIV-1 Infection with Early Antiretroviral Therapy. New England Journal of Medicine. 365:493-505 (2011)
INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. New England Journal of Medicine. 373, 795–807 (2015)
Rodger AJ, Cambiano V, Bruun T, et al. Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy. JAMA. 2016;316(2):171–181.
PARTNER 2 presented at AIDS 2018, published in 2019
Rodger AJ, et al. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. Lancet. (2019)
Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial Consortium. HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial. Lancet. 394(10195):303-313 (2019 June 13)
Swindells S et al. Long-acting cabotegravir + rilpivirine as maintenance therapy: ATLAS week 48 results. Conference on Retroviruses and Opportunistic Infections, Boston, abstract 139 LB (2019)
Overton ET et al. Cabotegravir + rilpivirine every 2 months is noninferior to monthly: ATLAS-2M study. Conference on Retroviruses and Opportunistic Infections, abstract 34 (March 2020)
Jaeger H et al. Week 96 efficacy and safety of cabotegravir + rilpivirine every 2 months: ATLAS-2M. Conference on Retroviruses and Opportunistic Infections, abstract 401 (2021)
Long-acting injectable form of HIV prevention outperforms daily pill in NIH study. Presented at HIVR4P 2021.